

Korea's LegoChemBio buys first-in-class antibody from Swiss startup for cancer therapy

15 February 2023 | News

To advance this potentially fifth LegoChemBio platform-generated ADC candidate into clinic



South Korea's LegoChem Biosciences Inc. has announced a license agreement with Elthera AG, a biotechnology startup in Switzerland, to develop and commercialise a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.

The licensed asset is a monoclonal antibody with a target expressed in a variety of solid tumours including pancreatic, ovarian, breast, lung, and colorectal cancer. Under the terms of the agreement, LegoChemBio will be responsible for the future development and commercialisation of any products incorporating this antibody.

Elthera will receive an upfront payment and is eligible to receive progress-dependent development and regulatory milestone payments as well as cumulative commercial milestone payments. Elthera will additionally receive royalties on net product sales.

Anne Schmidt, CEO of Elthera said, "This agreement is the result of a fruitful collaboration with LegoChemBio, demonstrating the outstanding quality and therapeutic potential of our antibody. The combination with LegoChemBio's ConjuAll technology generates a well-differentiated first-in class ADC with a wide therapeutic window that has the potential to provide new treatment options for a large number of solid tumours."